Thilo Schroeder
About Thilo Schroeder
Thilo Schroeder, Ph.D., age 43, has served as an independent director of Revolution Medicines since March 2018. He is Managing Partner at Nextech Invest Ltd., an oncology-focused venture firm (since 2012), and holds a Ph.D. in Biochemistry (University of Zurich), M.S. in Biotechnology (École de Supérieure de Biotechnologie de Strasbourg), and B.S. in Biology (Technical University of Darmstadt) . The Board has determined he is independent under Nasdaq rules .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Nextech Invest Ltd. | Managing Partner | 2012–present | Oncology-focused VC leadership |
| Academic research (DARPins) | Researcher | 2007–2012 | Protein inhibitor development focus |
External Roles
| Company | Role | Status/Notes |
|---|---|---|
| PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) | Director | Previously served |
| IDEAYA Biosciences, Inc. (Nasdaq: IDYA) | Director | Previously served |
| Silverback Therapeutics, Inc. | Director | Previously served; company later acquired by ARS Pharmaceuticals |
Board Governance
- Committee assignments: Audit Committee member (not chair) .
- Independence: Board-designated independent director; all committees he serves on consist solely of independent directors .
- Attendance and engagement: In 2024, the Board met 8x; Audit met 4x; each director attended ≥75% of their Board and committee meetings .
- Tenure: Director since 2018 .
- Lead Independent Director: Alexis Borisy (context) .
Fixed Compensation
| Year | Cash Fees ($) | Stock Awards ($) | Option Awards ($) | Total ($) |
|---|---|---|---|---|
| 2024 | — | — | — | — |
- Note: Dr. Schroeder waived compensation for Board service; he received no cash retainers or equity grants as a director .
Performance Compensation
- None. The proxy discloses no performance-based director compensation for Dr. Schroeder given his waiver of director pay .
Other Directorships & Interlocks
- Network/Interlocks:
- Schroeder is Managing Partner at Nextech Invest; Nextech-affiliated funds are significant RVMD shareholders (see Equity Ownership). Another RVMD director, Alexis Borisy, serves as Chairman of Nextech’s board, creating a notable interlock between an RVMD director and a major shareholder’s advisor/board chair .
- Related-party oversight context: RVMD’s Tango Therapeutics collaboration involved two other RVMD directors (Weber, CEO of TNGX; Borisy, TNGX director) and was approved by the Audit Committee under the related-party policy; Schroeder serves on the Audit Committee that oversees related-person transactions .
Expertise & Qualifications
- Oncology investing/operator perspective via Nextech; prior scientific research in protein therapeutics; advanced scientific education .
- Audit Committee: meets SEC/Nasdaq independence and literacy standards; Audit Committee financial experts designated are Lorence Kim and Sushil Patel (Schroeder not designated as “financial expert”) .
Equity Ownership
| Holder (affiliation noted in footnote) | Shares | Ownership form | Notes |
|---|---|---|---|
| Nextech V Oncology S.C.S., SICAV-SIF | 3,590,313 | Indirect | Advised by Nextech Invest AG |
| Nextech VI Oncology SCSp | 1,153,293 | Indirect | Advised by Nextech Invest AG |
| Nextech Crossover I SCSp | 2,096,612 | Indirect | Advised by Nextech Invest AG |
| Nextech VIII SCSP | 760,869 | Indirect | Advised by Nextech Invest AG |
| Total beneficially owned (reported under Schroeder) | 7,601,087 | Indirect | 4.1% of outstanding; Schroeder disclaims beneficial ownership except to extent of pecuniary interests |
Policy guardrails:
- Insider policy prohibits hedging and pledging by directors; no pledging disclosed for Schroeder .
Insider Trades (Form 4)
| Transaction Date | Type | Shares | Price ($) | Ownership After | Ownership Type | Source |
|---|---|---|---|---|---|---|
| 2024-12-05 | Open-market purchase | 543,478 | 46.00 | 2,096,612 | Indirect (Nextech Crossover I) | https://www.sec.gov/Archives/edgar/data/1628171/000141588924028638/0001415889-24-028638-index.htm |
| 2024-12-05 | Open-market purchase | 760,869 | 46.00 | 760,869 | Indirect (Nextech VIII) | https://www.sec.gov/Archives/edgar/data/1628171/000141588924028638/0001415889-24-028638-index.htm |
- Reporting name: “Schroeder Thilo” (director). Both purchases were reported as indirect acquisitions by affiliated Nextech funds; filing date 2024-12-09 [SEC URLs above].
Governance Assessment
- Alignment and signals:
- Strong ownership alignment via significant economic exposure through Nextech funds (aggregate 7.6M shares; 4.1% of RVMD), plus personal decision to waive director compensation—both are positive signals for investor alignment .
- Insider activity: Indirect open-market purchases by Nextech-affiliated entities at $46 in December 2024 suggest high-conviction support during RVMD’s late-stage pipeline transition—supportive for confidence (indirect but meaningful) [SEC URLs above].
- Governance quality:
- Independent status; active Audit Committee membership; Board attendance threshold met (≥75%)—all supportive of board effectiveness .
- Related-party risk is present given (i) Nextech’s large stake and Borisy’s chair role at Nextech, and (ii) other director-linked collaboration with Tango; mitigants include Audit Committee oversight and application of RVMD’s related-person transaction policy .
- No hedging/pledging allowed by policy; no pledging disclosed—a key risk mitigant .
RED FLAGS to monitor: Potential perceived influence of a large shareholder (Nextech) with two RVMD directors connected to it (Schroeder as Nextech Managing Partner; Borisy as Nextech Chairman) warrants continued scrutiny of recusals and Audit Committee processes on any transactions or decisions that could benefit Nextech funds distinctly from all shareholders .
Citations:
- Board composition, ages, tenure, committees: .
- Biography and education: .
- Independence determination: .
- Attendance: .
- Director compensation program and waiver: .
- Beneficial ownership table and Nextech breakdown: .
- Insider trading policy (hedging/pledging prohibition): .
- Interlocks (Borisy—Nextech chair): .
- Related-party transaction with Tango and Audit approval: .